Few in proteomics had probably ever heard of Danaher until two weeks ago. But the once-struggling real estate investment trust has been transformed by the Rales brothers into a successful global conglomerate, and by the end of the year is poised to become the top mass-spec firm in the world with the purchase of the ABI/MDS joint venture.
Omic is the second spinout formed by UMBI in as many months, even as the institute, which is part of the University System of Maryland, is currently transitioning various components of its operations to other UM campuses in a bid to maximize research collaborations and boost external funding.
Danaher will spend $1.1 billion to acquire the mass spec joint venture of MDS and Life Technologies, as well as the Molecular Devices business owned by MDS. It expects those businesses to add $650 million in annual revenues to its life sciences segment.
Boston University School of Medicine researcher Catherine Costello plans to add a Bruker solariX system to the institute's mass spec resource and also will collaborate with the company to develop new glycomics and proteomics-related mass spec approaches.
Researchers in the Netherlands have identified 44 protein biomarkers that appear repeatedly in 2D gel electrophoresis-based disease biomarker studies and have linked them to cellular stress response, adding "in future proteomic studies, more profound approaches should be applied to look beyond these proteins to find specific biomarkers."
The survey conducted by Leerink Swann found that 31 percent of university-based researchers consider capital-equipment purchases their top budget priority, and within that group, 35 percent cited mass specs as their single biggest priority.
As performance-enhancing drugs have evolved from small molecules to substances that traditional test methods cannot detect, Quotient Bioresearch is developing a biomarker-based approach to test not for specific molecules in a horse's system but for biological changes that could be indications of doping.
The system, called Lucid Proteomics, combining Bio-Rad's SELDI-based array technology with Bruker's ultrafleXtreme MALDI-TOF/TOF instrument, is expected to hit the market in late summer or early fall, and is the first fruit of a co-marketing and co-development collaboration between the two firms announced a month ago.
The center, created with a $113 million grant from the Novo Nordisk Foundation, will eventually operate at least nine mass specs, as well as liquid chromatographs and various protein-expression and characterization tools.
For the three months ended April 30, the company, which has a joint-venture agreement with Life Technologies' Applied Biosystems on mass specs, said its Analytical Technologies revenues fell to $87 million, down from $118 million in Q2 2008.